Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of thermostable tetanus-diphtheria vaccine SPVX02 versus Tetadif
ISRCTN17148628Phase 2Recruiting
- Sponsor
- Stablepharma
- Start
- Aug 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial in Tetanus and diphtheria comparing SPVX02 with Tetadif (2 arms). Primary endpoint: Seroprotection at Day 28. Started Aug 2026; status: recruiting.
02
Drugs
SPVX02Tetadif
03
Conditions
Tetanusdiphtheria
Beyond the preview
Go deeper on ISRCTN17148628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN17148628.